Genetic testing all women for breast cancer might not be worth the cost

Women who are carriers of mutated BRCA genes are known to have a significantly higher risk for developing breast and ovarian cancers than those who don’t. But a new study by UCLA faculty questions the value of screening for the genetic mutations in the general population — including those who do not have cancer or have no family history of the disease — because of the high cost. The UCLA researchers found that compared with universal screening, other diagnostic tools remain more efficient and might be more cost-effective.  The paper was authored by Dr. Patricia Ganz, director of the division of cancer prevention and control research at UCLA’s Jonsson Comprehensive Cancer Center, and Elisa Long, assistant professor at the UCLA Anderson School of Management. The researchers concluded the BRCA genetic test that is most widely used today — marketed by Myriad Genetics, it sells for about $4,000 — is too expensive to warrant universal screening, given how rare BRCA mutations are. “The cost of BRCA testing would need to drop by 90 percent for testing to be cost-effective for the whole population,” Ganz said. Long and Ganz calculated that for every 10,000 women screened, BRCA screening could avert  four cases of breast cancer and two cases of ovarian cancer more than family history-based testing would. But the BRCA screening would only extend patients’ life by an average of two days. For 99.75 percent of women screened, ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

ConclusionsThe mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T  >  G and c.5266dupCBRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively.
Source: Hereditary Cancer in Clinical Practice - Category: Cancer & Oncology Source Type: research
Introduction: Ovarian cancer is usually detected by peritoneal carcinomatosis with ascites.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Movies Case Reports 6 – Oncology Source Type: research
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019 Jan 09;: Authors: Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA Abstract OBJECTIVE: To analyze the safety and efficacy of niraparib in patients aged ≥70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial. ...
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Tags: Gynecol Oncol Source Type: research
Publication date: Available online 28 October 2018Source: Pathology - Research and PracticeAuthor(s): Miguel Barquín, Constanza Maximiano, Clara Pérez-Barrios, Estela Sanchez-Herrero, María Soriano, Marta Colmena, Manuel García-Espantaleón, Eva Tejerina González, Lourdes Gutierrez, Antonio Carlos Sánchez Ruiz, María Torrente, Mariano Provencio, Atocha RomeroAbstractGenetic screening for BRCA mutations should be offered to all women diagnosed with epithelial ovarian, fallopian tube, and/or peritoneal cancers given the implications for treatment options and cancer risk ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
, Torrente M, Provencio M, Romero A Abstract Genetic screening for BRCA mutations should be offered to all women diagnosed with epithelial ovarian, fallopian tube, and/or peritoneal cancers given the implications for treatment options and cancer risk assessments. Yet, while germline breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) testing is commonly performed, BRCA1/2 somatic mutations testing is rather challenging since the poor quality of DNA extracted from formalin fixed paraffin embedded (FFPE) samples can significantly impair this process. Peritoneal lavage is routi...
Source: Pathology, Research and Practice - Category: Pathology Authors: Tags: Pathol Res Pract Source Type: research
Condition:   HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer Interventions:   Drug: PF-06873600;   Drug: Endocrine Therapy 1;   Drug: Endocrine Therapy 2 Sponsor:   Pfizer Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This report describes the first case of peritoneal carcinoma arising after RRSO in a Japanese patient with BRCA1 mutation, including a review of the literature on peritoneal carcinoma associated with BRCA1/2 mutation. PMID: 29094253 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
More News: Breast Cancer | Breast Needle Aspiration | Breast Surgery | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Health | Mammography | Mastectomy | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study | Universities & Medical Training | Women